Neurotechnology
Paradromics
Developer of the Connexus brain-computer interface, a wireless implant designed to record and decode brain signals at the individual-neuron level to restore communication for patients with severe speech impairment. Neurosurgeons at University of Michigan Health completed the first-in-human implantation of the wireless Connexus BCI in 2026 as part of the multi-site Connect-One clinical study, following FDA approval of the study and Paradromics' acceptance into an FDA regulatory accelerator program with a new patient registry.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 69% avg. source confidence
- Michigan Medicine — University of Michigan implants first-in-human Paradromics wireless BCI74% source confidence
- BioSpace / Paradromics — Paradromics accepted into FDA regulatory accelerator program, adds third clinical trial site64% source confidence
Dependency Map
What Paradromics depends on below, and who depends on Paradromics above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Paradromics's Timeline
A sourced, dated history of Paradromics's key moments — founding to present.
Jan 2015 · Founded
Paradromics was founded to develop high-bandwidth, wireless brain-computer interfaces for restoring communication in patients with severe speech impairment.
Jan 2026 · First-in-human Connexus implant at University of Michigan
Neurosurgeons at University of Michigan Health completed the first-in-human implantation of Paradromics' wireless Connexus brain-computer interface, part of the national multi-site Connect-One clinical study following FDA approval.